Acepodia is actively seeking partners who are interested in collaborating to develop innovative and highly effective cell therapies for patients with cancer and other diseases with unmet medical needs. We believe our ACC technologies can significantly advance the field of cellular therapeutics through directing allogeneic effector cells by conjugated antibodies. Furthermore, CD16 expression confers our proprietary γδ2T cells with ADCC activity, which leverage the efficacy of clinically used mAb.